Printer Friendly
The Free Library
19,585,946 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Allergan, Inc. Announces the Effectiveness of Its Registration Statement.


Business Editors

IRVINE, Calif.--(BUSINESS WIRE)--Dec. 8, 2000

Allergan, Inc. (NYSE NYSE

See: New York Stock Exchange
: AGN AGN Again (Amateur Radio)
AGN Active Galactic Nucleus
AGN Acute Glomerulonephritis
AGN Accountants Global Network
AGN Air Gabon (ICAO code) 
), today announced that the Securities and Exchange Commission has declared its Registration Statement on Form S-3, registering its zero coupon convertible subordinated notes due November 1, 2020 and the shares of common stock of the Company into which the notes are convertible, effective as of December 8, 2000 at 9:00 a.m. EST EST electroshock therapy.

EST
abbr.
electroshock therapy
. This news release does not constitute an offer to sell or the solicitation solicitation

In criminal law, the act of asking, inducing, or directing someone to commit a crime. The person soliciting another becomes an accomplice to the crime. The term also refers to the act of obtaining bribes, as well as to the crime of a prostitute who offers sexual
 of an offer to buy the securities.
COPYRIGHT 2000 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Dec 8, 2000
Words:87
Previous Article:Pacific Magtron International Corp. Reports Third Quarter and Nine Month Results.
Next Article:Sunrise Medical Athletes Win Three of Four Titles in Paralympic Tennis.
Topics:



Related Articles
Allergan and Ligand form new research and development corporation to raise $100 million; File unit offering for $32.5 million.
Record date set for offering of rights to purchase units of Allergan Ligand Retinoids Therapeutic Inc.
Ligand and Allergan Announce Buyout of Allergan Ligand Retinoid Therapeutics Inc.
Allergan Chooses Dendrite's SalesPlus for Five Sales Teams; Dendrite Signs First West Coast Pharmaceutical Company to Three Year Deal.
Allergan Chooses Dendrite's SalesPlus for Five Sales Teams.
Allergan and Dura Pharmaceuticals Enter Into Segment Alliance Agreement to Promote Multiple Products.
Allergan's Tazorac Receives U.S. FDA Approval for a New Cream Formulation.
Allergan Reports Fourth Quarter and Year-End Operating Results.
Dendrite Selected to Provide Integral Link for Product Representatives at Allergan; WebForce Solution Chosen to Support Leading Product Line.
Advanced Medical Optics Intends to Raise $200 Million Through a 144A Private Placement of Senior Subordinated Notes.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles